Key regions: Australia, Germany, United Kingdom, United States, France
The demand for immunosuppressants in Mauritius has been on a steady rise in recent years.
Customer preferences: The increase in demand for immunosuppressants in Mauritius can be attributed to the rise in the number of people suffering from autoimmune diseases. These diseases, such as lupus, rheumatoid arthritis, and multiple sclerosis, affect the immune system, leading to chronic inflammation and tissue damage. As a result, patients require medication to suppress their immune systems and prevent further damage.
Trends in the market: The trend in Mauritius is similar to the global trend, where the market for immunosuppressants is expected to grow in the coming years. This growth can be attributed to the increasing prevalence of autoimmune diseases, advancements in technology, and the rising demand for organ transplants. Furthermore, the introduction of new drugs and therapies in the market is expected to drive the growth of the immunosuppressants market in Mauritius.
Local special circumstances: Mauritius has a small population, which means that the market for immunosuppressants is relatively small. However, the country has a high prevalence of autoimmune diseases, which has led to an increase in demand for immunosuppressant drugs. Additionally, the government of Mauritius has taken steps to improve the healthcare infrastructure in the country, which has led to an increase in the availability of immunosuppressant drugs.
Underlying macroeconomic factors: The growth of the immunosuppressants market in Mauritius is also influenced by underlying macroeconomic factors such as the country's GDP, healthcare spending, and government policies. Mauritius has a growing economy, which has led to an increase in healthcare spending. This increase in spending has led to an improvement in the healthcare infrastructure in the country, which has led to an increase in the availability of immunosuppressant drugs. Additionally, the government of Mauritius has implemented policies to improve access to healthcare for all citizens, which has further increased the demand for immunosuppressants.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
